Literature DB >> 1498071

Retinoids in cancer prevention and therapy.

W Bollag1, E E Holdener.   

Abstract

Retinoids are a class of compounds structurally related to vitamin A. In preclinical studies, all-trans retinoic acid (tretinoin), 13-cis retinoic acid (isotretinoin) and the aromatic retinoids etretinate and acitretin have preventive and therapeutic effects on carcinogen-induced premalignant and malignant lesions. Clinically, chemoprevention with isotretinoin and etretinate has been tested with some degree of success in such indications as basal cell carcinomas, squamous cell carcinomas, superficial bladder tumors and second primary tumors in patients with squamous cell carcinoma of the head and neck. Limited therapeutic success has also been achieved with retinoid treatment of precancerous and cancerous conditions of the skin, oral cavity, larynx, lung, bladder and vulva. Dramatic therapeutic effects have been observed in the treatment of acute promyelocytic leukemia with tretinoin, which leads to very high rate of complete remission. Excellent results were recently reported in the treatment of squamous cell carcinomas of the skin and cervix with a combination of isotretinoin and recombinant interferon alfa-2a (rIFN alfa-2a, Roferon-A). The mechanism of action of retinoids is through modulation of cell proliferation and differentiation. Retinoids vary in their capacity to induce differentiation and to inhibit proliferation in a series of human transformed hematopoietic and epithelial cell lines. Some cytokines potentiate the retinoid-induced cell differentiation and act synergistically with retinoids to inhibit cell proliferation. The pattern of synergism is dependent upon the combination and tumor cell line tested. The discovery of nuclear retinoid receptors has contributed substantially to the understanding of the mechanism of action of retinoids at the molecular level. Further understanding of the molecular biology of retinoids is expected to contribute to a rational design of new retinoids in the future, which in turn may result in improvements in the prevention and therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1498071     DOI: 10.1093/oxfordjournals.annonc.a058252

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  23 in total

Review 1.  Unconventional therapies for cancer: 5. Vitamins A, C and E. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.

Authors:  E Kaegi
Journal:  CMAJ       Date:  1998-06-02       Impact factor: 8.262

2.  The receptor-DNA complex determines the retinoid response: a mechanism for the diversification of the ligand signal.

Authors:  N La Vista-Picard; P D Hobbs; M Pfahl; M I Dawson; M Pfahl
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

Review 3.  Current use and future potential role of retinoids in dermatology.

Authors:  C E Orfanos; C C Zouboulis; B Almond-Roesler; C C Geilen
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

4.  Vitamin A enhances antitumor effect of a green tea polyphenol on melanoma by upregulating the polyphenol sensing molecule 67-kDa laminin receptor.

Authors:  Ju Hye Lee; Mutsumi Kishikawa; Motofumi Kumazoe; Koji Yamada; Hirofumi Tachibana
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

5.  The high sensitivity of the rabbit to the teratogenic effects of 13-cis-retinoic acid (isotretinoin) is a consequence of prolonged exposure of the embryo to 13-cis-retinoic acid and 13-cis-4-oxo-retinoic acid, and not of isomerization to all-trans-retinoic acid.

Authors:  G Tzimas; H Bürgin; M D Collins; H Hummler; H Nau
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

6.  Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential.

Authors:  Martin Conda-Sheridan; Eun-Jung Park; Daniel E Beck; P V Narasimha Reddy; Trung X Nguyen; Bingjie Hu; Lian Chen; Jerry J White; Richard B van Breemen; John M Pezzuto; Mark Cushman
Journal:  J Med Chem       Date:  2013-03-08       Impact factor: 7.446

7.  Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study.

Authors:  Caecilia Wismeth; Peter Hau; Klaus Fabel; Ulrike Baumgart; Birgit Hirschmann; Horst Koch; Tanja Jauch; Oliver Grauer; Lisa Drechsel; Alexander Brawanski; Ulrich Bogdahn; Andreas Steinbrecher
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

Review 8.  The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression.

Authors:  O V Volpert; V Stellmach; N Bouck
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

9.  Retinoic Acid Induces Apoptosis of Prostate Cancer DU145 Cells through Cdk5 Overactivation.

Authors:  Mei-Chih Chen; Chih-Yang Huang; Shih-Lan Hsu; Eugene Lin; Chien-Te Ku; Ho Lin; Chuan-Mu Chen
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-13       Impact factor: 2.629

10.  RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation.

Authors:  J Y Chen; S Penco; J Ostrowski; P Balaguer; M Pons; J E Starrett; P Reczek; P Chambon; H Gronemeyer
Journal:  EMBO J       Date:  1995-03-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.